The strategies to overcome resistance to ALK inhibitor in lung cancer.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462193
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Chiba Cancer Center (Research Institute)
• Principal Investigator: Yokoi Sana 千葉県がんセンター(研究所), がんゲノムセンター, 部長 (30372452)
• Co-Investigator(Kenkyū-buntansha): Iizasa Toshihiko 千葉県がんセンター, 呼吸器外科, 部長 (10272303)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 肺癌

Outline of Final Research Achievements

Anaplastic lymphoma kinase (ALK) which is one of the receptor tyrosine kinase is activated by chromosomal translocation and causes lung cancer (ALK lung cancer). ALK inhibitor shows remarkable effect for ALK lung cancer. However, ALK lung cancer becomes tolerance to ALK inhibitor in short time. To find a new therapeutic target for ALK lung cancer, the genomic abnormality was analyzed. As a result, we found a putative candidate gene which is decreased expression in ALK lung cancer by genomic deletion or DNA methylation in promoter region. A forced expression of this gene leads to the growth retardation in lung cancer cell line with ALK translocation.

Free Research Field

腫瘍遺伝学